AZ sells Rhinocoart Aqua rights to Cilag
AstraZeneca has completed the sale of rights to nasal spray Rhinocort Aqua to Johnson & Johnson group Cilag GmbH.
Read More
Tag: Rhinocort
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
